

ADVANCES IN CANCER RESEARCH

Volume 14

ADVANCES IN CANCER RESEARCH

Edited by

GEORGE KLEIN

Department of Tumor Biology
Karolinska Institutet
Stockholm, Sweden

SIDNEY WEINHOUSE

Fels Research Institute
Temple University Medical School
Philadelphia, Pennsylvania

Consulting Editor

ALEXANDER HADDOW

Chester Beatty Research Institute
Institute of Cancer Research
Royal Cancer Hospital
London, England

Volume 14



ACADEMIC PRESS

New York and London

1971

ADVANCES IN
CANCER RESEARCH

Edited by

GEORGE KLEIN
Department of Tumor Biology
Karolinska Institute
Stockholm, Sweden

COPYRIGHT © 1971, BY ACADEMIC PRESS, INC.

ALL RIGHTS RESERVED

**NO PART OF THIS BOOK MAY BE REPRODUCED IN ANY FORM, BY
PHOTOSTAT, MICROFILM, RETRIEVAL SYSTEM, OR ANY OTHER
MEANS, WITHOUT WRITTEN PERMISSION FROM THE PUBLISHERS.
REPRODUCTION IN WHOLE OR IN PART FOR ANY PURPOSE OF THE
UNITED STATES GOVERNMENT IS PERMITTED.**

ACADEMIC PRESS, INC.
111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by
ACADEMIC PRESS, INC. (LONDON) LTD.
Berkeley Square House, London W1X 6BA

LIBRARY OF CONGRESS CATALOG CARD NUMBER: 52-13360

PRINTED IN THE UNITED STATES OF AMERICA



ADVANCES IN CANCER RESEARCH

VOLUME 14

Ernest Winocour
Alice Stewart
Kazuo Nishio
Roland Motto

George Meyer
Donald Metcalf
George Mathé
G. J. Abel

Contributors to This Volume

G. I. Abelev

Georges Mathé

Donald Metcalf

Georges Meyer

Roland Motta

Kusuya Nishioka

Alice Stewart

Ernest Winocour

CONTRIBUTORS TO VOLUME 14

Numbers in parentheses refer to the pages on which the authors' contributions begin.

G. I. ABELEV, *Laboratory of Tumor Immunochemistry, N. F. Gamaleya Institute for Epidemiology and Microbiology, Moscow, USSR* (295)

GEORGES MATHÉ, *Institut de Cancérologie et d'Immunogénétique, Hôpital Paul-Brousse, 94-Villejuif, France* (1)

DONALD METCALF, *Cancer Research Unit, Walter and Eliza Hall Institute, Melbourne, Australia* (181)

GEORGES MEYER, *Research Department of the Regional Cancer Center of Marseilles, 13, Marseilles, France* (71)

ROLAND MOTTA, *Institut de Cancérologie et d'Immunogénétique, Hôpital Paul-Brousse, 94-Villejuif, France and Unité de Génétique, Université Paris VI, Paris, France* (161)

KUSUYA NISHIOKA, *Virology Division, National Cancer Center Research Institute, Tokyo, Japan* (231)

ALICE STEWART, *Department of Social Medicine, Oxford University, Oxford, England* (359)

ERNEST WINOGOUR, *Department of Genetics, Weizmann Institute of Science, Rehovot, Israel* (37)

CONTENTS OF PREVIOUS VOLUMES

Volume 1

Electronic Configuration and Carcinogenesis

C. A. Coulson

Epidermal Carcinogenesis

E. V. Cowdry

The Milk Agent in the Origin of Mammary Tumors in Mice

L. Dmochowski

Hormonal Aspects of Experimental Tumorigenesis

T. U. Gardner

Properties of the Agent of Rous No. 1 Sarcoma

R. J. C. Harris

Applications of Radioisotopes to Studies of Carcinogenesis and Tumor Metabolism

Charles Heidelberger

The Carcinogenic Aminoazo Dyes

James A. Miller and Elizabeth C. Miller

The Chemistry of Cytotoxic Alkylating Agents

M. C. J. Röss

Nutrition in Relation to Cancer

Albert Tannenbaum and Herbert Silverstone

Plasma Proteins in Cancer

Richard J. Winzler

AUTHOR INDEX—SUBJECT INDEX

Volume 2

The Reactions of Carcinogens with Macromolecules

Peter Alexander

Chemical Constitution and Carcinogenic Activity

G. M. Badger

Carcinogenesis and Tumor Pathogenesis

I. Berenblum

Ionizing Radiations and Cancer

Austin M. Brues

Survival and Preservation of Tumors in the Frozen State

James Craigie

Energy and Nitrogen Metabolism in Cancer

Leonard D. Fenninger and G. Burroughs Mider

Some Aspects of the Clinical Use of Nitrogen Mustards

Calvin T. Klopp and Jeanne C. Bateman

Genetic Studies in Experimental Cancer

L. W. Law

The Role of Viruses in the Production of Cancer

C. Oberling and M. Guerin

Experimental Cancer Chemotherapy

C. Chester Stock

AUTHOR INDEX—SUBJECT INDEX

Volume 3

Etiology of Lung Cancer

Richard Doll

The Experimental Development and Metabolism of Thyroid Gland Tumors

Harold P. Morris

Electronic Structure and Carcinogenic Activity and Aromatic Molecules: New Developments

A. Pullman and B. Pullman

Some Aspects of Carcinogenesis

P. Rondoni

Pulmonary Tumors in Experimental Animals

Michael B. Shimkin

Oxidative Metabolism of Neoplastic
Tissues

Sidney Weinhouse

AUTHOR INDEX—SUBJECT INDEX

Volume 4

Advances in Chemotherapy of Cancer in
Man

*Sidney Farber, Rudolf Toch, Edward
Manning Sears, and Donald Pinkel*

The Use of Myleran and Similar Agents
in Chronic Leukemias

D. A. G. Galton

The Employment of Methods of Inhibition
Analysis in the Normal and
Tumor-Bearing Mammalian Organ-
ism

Abraham Goldin

Some Recent Work on Tumor Immunity

P. A. Gorer

Inductive Tissue Interaction in Develop-
ment

Clifford Grobstein

Lipids in Cancer

Frances L. Haven and W. R. Bloor

The Relation between Carcinogenic
Activity and the Physical and
Chemical Properties of Angular
Benzacridines

*A. Lacassagne, N. P. Buu-Hoi, R.
Daudel, and F. Zajdela*

The Hormonal Genesis of Mammary
Cancer

O. Mühlbock

AUTHOR INDEX—SUBJECT INDEX

Volume 5

Tumor-Host Relations

R. W. Begg

Primary Carcinoma of the Liver

Charles Berman

Protein Synthesis with Special Reference
to Growth Processes both Normal
and Abnormal

P. N. Campbell

The Newer Concept of Cancer Toxin

Waro Nakahara and Fumiko Fukuoka

Chemically Induced Tumors of Fowls

P. R. Peacock

Anemia in Cancer

*Vincent E. Price and Robert E.
Greenfield*

Specific Tumor Antigens

L. A. Zilber

Chemistry, Carcinogenicity, and Metab-
olism of 2-Fluorenamine and Related
Compounds

*Elizabeth K. Weisburger and John H.
Weisburger*

AUTHOR INDEX—SUBJECT INDEX

Volume 6

Blood Enzymes in Cancer and Other
Diseases

Oscar Bodansky

The Plant Tumor Problem

Armin C. Braun and Henry N. Wood

Cancer Chemotherapy by Perfusion

*Oscar Creech, Jr., and Edward T.
Krementz*

Viral Etiology of Mouse Leukemia

Ludwik Gross

Radiation Chimeras

*P. C. Koller, A. J. S. Davies, and
Sheila M. A. Doak*

Etiology and Pathogenesis of Mouse
Leukemia

J. F. A. P. Miller

Antagonists of Purine and Pyrimidine
Metabolites and of Folic Acid

G. M. Timmis

Behavior of Liver Enzymes in Hepato-
carcinogenesis

George Weber

AUTHOR INDEX—SUBJECT INDEX

Volume 7

Avian Virus Growths and Their Etiologic
Agents

J. W. Beard

Mechanisms of Resistance to Anticancer Agents

R. W. Brockman

Cross Resistance and Collateral Sensitivity Studies in Cancer Chemotherapy

Dorris J. Hutchison

Cytogenic Studies in Chronic Myeloid Leukemia

W. M. Court Brown and Ishbel M. Tough

Ethionine Carcinogenesis

Emmanuel Farber

Atmospheric Factors in Pathogenesis of Lung Cancer

Paul Kotin and Hans L. Falk

Progress with Some Tumor Viruses of Chickens and Mammals: The Problem of Passenger Viruses

G. Negróni

AUTHOR INDEX—SUBJECT INDEX

Volume 8

The Structure of Tumor Viruses and Its Bearing on Their Relation to Viruses in General

A. F. Howatson

Nuclear Proteins of Neoplastic Cells

Harris Busch and William J. Steele

Nucleolar Chromosomes: Structures, Interactions, and Perspectives

M. J. Kopac and Gladys M. Mateyko

Carcinogenesis Related to Foods Contaminated by Processing and Fungal Metabolites

H. F. Kraybill and M. B. Shimkin

Experimental Tobacco Carcinogenesis

Ernest L. Wynder and Dietrich Hoffmann

AUTHOR INDEX—SUBJECT INDEX

Volume 9

Urinary Enzymes and Their Diagnostic Value in Human Cancer

Richard Stambaugh and Sidney Weinhouse

The Relation of the Immune Reaction to Cancer

Louis V. Caso

Amino Acid Transport in Tumor Cells

R. M. Johnstone and P. G. Scholefield

Studies on the Development, Biochemistry, and Biology of Experimental Hepatomas

Harold P. Morris

Biochemistry of Normal and Leukemic Leucocytes, Thrombocytes, and Bone Marrow Cells

I. F. Seitz

AUTHOR INDEX—SUBJECT INDEX

Volume 10

Carcinogens, Enzyme Induction, and Gene Action

H. V. Gelboin

In Vitro Studies on Protein Synthesis by Malignant Cells

A. Clark Griffin

The Enzymatic Pattern of Neoplastic Tissue

W. Eugene Knox

Carcinogenic Nitroso Compounds

P. N. Magee and J. M. Barnes

The Sulfhydryl Group and Carcinogenesis

J. S. Harington

The Treatment of Plasma Cell Myeloma

Daniel E. Bergsagel, K. M. Griffith, A. Haut, and W. J. Stuckey, Jr.

AUTHOR INDEX—SUBJECT INDEX

Volume 11

The Carcinogenic Action and Metabolism of Urethan and N-Hydroxyurethan

Sidney S. Mirvish

Runting Syndromes, Autoimmunity, and Neoplasia

D. Keast

Viral-Induced Enzymes and the Problem of Viral Oncogenesis

Saul Kit

The Growth-Regulating Activity of Polyanions: A Theoretical Discussion of Their Place in the Inter-cellular Environment and Their Role in Cell Physiology

William Regelson

Molecular Geometry and Carcinogenic Activity of Aromatic Compounds. New Perspectives

Joseph C. Arcos and Mary F. Argus

AUTHOR INDEX—SUBJECT INDEX

CUMULATIVE INDEX

Volume 12

Antigens Induced by the Mouse Leukemia Viruses

G. Pasternak

Immunological Aspects of Carcinogenesis by Deoxyribonucleic Acid Tumor Viruses

G. I. Deichman

Replication of Oncogenic Viruses in Virus-Induced Tumor Cells—Their Persistence and Interaction with Other Viruses

H. Hanafusa

Cellular Immunity against Tumor Antigens

Karl Erik Hellström and Ingegerd Hellström

Perspectives in the Epidemiology of Leukemia

Irving I. Kessler and Abraham M. Lilienfeld

AUTHOR INDEX—SUBJECT INDEX

Volume 13

The Role of Immunoblasts in Host Resistance and Immunotherapy of Primary Sarcoma

P. Alexander and J. G. Hall

Evidence for the Viral Etiology of Leukemia in the Domestic Mammals

Oswald Jarrett

The Function of the Delayed Sensitivity Reaction as Revealed in the Graft Reaction Culture

Haim Ginsburg

Epigenetic Processes and Their Relevance to the Study of Neoplasia

Gajanan V. Sherbet

The Characteristics of Animal Cells Transformed *in Vitro*

Ian Macpherson

Role of Cell Association in Virus Infection and Virus Rescue

J. Svoboda and I. Hložánek

Cancer of the Urinary Tract

D. B. Clayson and E. H. Cooper

Aspects of the EB Virus

M. A. Epstein

AUTHOR INDEX—SUBJECT INDEX

CONTENTS

CONTRIBUTORS TO VOLUME 14	ix
CONTENTS OF PREVIOUS VOLUMES	ix

Active Immunotherapy

GEORGES MATHÉ

I. Introduction	1
II. Experimental Basis	2
III. Clinical Trials	18
IV. Conclusions and Perspectives	30
References	31

The Investigation of Oncogenic Viral Genomes in Transformed Cells by Nucleic Acid Hybridization

ERNEST WINOCOUR

I. Introduction	37
II. Viral DNA Sequences in the DNA of Transformed Cells	40
III. Transcription of the Viral Genome in the Transformed Cells	53
IV. Discussion and Conclusions	63
References	67

Viral Genome and Oncogenic Transformation: Nuclear and Plasma Membrane Events

GEORGES MEYER

I. Introduction	71
II. Nuclear Modifications	95
III. Cell Surface Modifications	117
IV. General Conclusions	150
References	153

Passive Immunotherapy of Leukemia and Other Cancer

ROLAND MOTTA

I. Introduction	161
II. Experimental Basis	162
III. Clinical Applications	173
IV. Conclusion	174
References	174

Humoral Regulators in the Development and Progression of Leukemia

DONALD METCALF

I. Introduction	181
II. General Principles Established with Endocrine Tumors	183
III. Regulation of Hematopoiesis	185
IV. Nonspecific Humoral Regulators of Hematopoiesis and Their Influence on Leukemia Development	191
V. Abnormalities in Humoral Regulators in the Preleukemic Period	194
VI. Humoral Regulator Levels in Leukemia	204
VII. Production of Humoral Factors by Leukemic Cells	209
VIII. Responsiveness of Leukemic Cells to Humoral Regulators	213
IX. Nature of Remissions in Acute Leukemia	219
X. General Discussion	220
References	224

Complement and Tumor Immunology

KUSUYA NISHIOKA

I. Introduction	231
II. Cell Receptors—New Immunological Cell Markers	234
III. Cellular Antigen as an Immunological Marker—General Considerations	245
IV. Immune Adherence	249
V. C1 Fixation and Transfer Reaction	265
VI. Complement Fixation Test	272
VII. Immune Cytotoxicity	275
VIII. Comments and Future Problems	283
References	285

Alpha-Fetoprotein in Ontogenesis and Its Association with Malignant Tumors

G. I. ABELEV

I. Introduction: Major Steps in Development of the Problem	295
II. Alpha-Fetoprotein Synthesis in Ontogenesis and Pathologic States. An Outline of the Phenomenon	297
III. Alpha-Fetoprotein (AFP). Definition and Physicochemical Character- istics	299
IV. Site of AFP Synthesis in Ontogenesis	307
V. The Dynamics of AFP in Ontogenesis	310
VI. AFP Synthesis during Regeneration of the Liver	318
VII. AFP in Hepatocellular Cancer	324
VIII. Clinical Aspects of the Diagnosis of Liver Cancer	345
IX. Alpha-Fetoprotein with Teratocarcinomas	349
X. Concluding Remarks	352
XI. Addendum	353
References	354

Low Dose Radiation Cancers in Man

ALICE STEWART

I. Introduction	359
II. Oxford Survey	363
III. Tissue Destructive Doses of Radiation	381
IV. Infections and Leukemia	383
V. Conclusions	386
References	388
AUTHOR INDEX	391
SUBJECT INDEX	414

ACTIVE IMMUNOTHERAPY

Georges Mathé

Institut de Cancérologie et d'Immunogénétique,
Hôpital Paul-Brousse, 94-Villejuif, France

I. Introduction	1
II. Experimental Basis	2
A. Specific Immunotherapy	2
B. Nonspecific Immunotherapy	4
C. Parameters of Action of Active Immunotherapy and Possible Side Effects	6
D. Modalities and Mechanisms of Action of Active Immunotherapy	11
E. The Special Case of Antitumor Immunotherapy Induced by Local Hypersensitivity Reactions	15
F. Strategy of Using Active Immunotherapy in Cancer	15
III. Clinical Trials	18
A. Treatment of Residual Disease	18
B. Use of Active Immunotherapy in Other Conditions of Malignant Disease	26
C. The Special Case of Antitumor Immunotherapy from Local Delayed Hypersensitivity Reaction to Another Antigen	30
IV. Conclusions and Perspectives	30
References	31

I. Introduction

Specific active immunotherapy is defined as the stimulation of immune reactions directed against tumor-associated antigens; nonspecific active immunotherapy is the general stimulation of the host's immune reactions by "adjuvants" of immunity.

There is an extensive literature on experimental immunological prevention, describing experiments in which the antitumor effects of immunization (Glynn *et al.*, 1963; Mathé *et al.*, 1969b) or stimulation of immune reactions (Old *et al.*, 1959; Biozzi *et al.*, 1960; Amiel, 1967; Mathé *et al.*, 1969b) have been tested by carrying out these procedures prior to grafting or inducing a tumor. On the other hand, far less attention has been paid to immunotherapy, the objective of which is to devise immunological procedures to inhibit established tumors. Immunotherapy is applicable to man at present, while our knowledge of tumor associated antigens in man is far too small to warrant any attempts at tumor prevention.

One of the main reasons for the paucity of experiments on specific immunization after grafting or inducing a tumor can be found by analogy between cancers and infections, against which immunotherapy is no longer used in a curative role. However, it now seems that when immunotherapy is used to cure cancer, it can sometimes be efficacious, though this varies according to different circumstances; but occasionally remarkable effects have been observed in several experimental systems and have already shown to act in man.

This review will be limited as far as possible to a consideration of isogenic tumors grafted into hosts with identical histocompatibility antigens, or autologous tumors, either induced by carcinogens or which occur spontaneously. Only passing reference will be made to studies on tumor grafted into incompatible hosts.

Clinical trials have often preceded studies in experimental animals or have been made at the same time. We made our first clinical trial of immunotherapy in acute lymphoblastic leukemia in 1964. Provided these trials are carried out in a scientific fashion, their results can be just as valuable as experiments in animals. However, the results of clinical and experimental studies will not be mixed in this article, but will be described consecutively.

II. Experimental Basis

A. SPECIFIC IMMUNOTHERAPY

Various antigenic stimulants can be used for specific immunotherapy, namely tumor cells, purified antigens, or oncogenic viruses.

1. Tumor Cells

In mice, grafted subcutaneously with 10^4 L 1210 leukemia cells, a significant increase of survival time has been obtained by injecting them 24 hours or even 4 days after grafting, with 10^7 isogenic leukemic cells irradiated with 15,000 rads *in vitro* (Mathé 1968; Mathé *et al.*, 1969b) (Fig. 1). In these experiments tumor cells had been injected subcutaneously, and the leukemia had been transmitted over so many generations that it might have produced a certain withdrawal of histocompatibility with the mice to which it had been grafted (the latter were F1(DBA/2 \times C57Bl/6) mice).

Two other experiments were made in which we treated mice, inoculated intravenously with 10^4 living cells of very recently induced leukemias. The RC19 leukemia, induced by Rauscher virus, and the E φ K1 leukemia, induced by Gross virus in C57Bl/6 mice were used. Specific active immunotherapy applied 24 hours after an isogenic graft of E φ K1 leukemia had a noticeable effect (Mathé *et al.*, 1971). Iris




FIG. 1. Tumor volume and cumulative survival of mice grafted with L 1210 leukemia and not treated or treated by BCG (first injection 24 hours after the graft and injections repeated each 4 days), or irradiated leukemic cells (one injection 24 hours after the graft), or association of both.

Parr (1971) obtained similar results on 5178Y tumor grafted intraperitoneally with 10^4 live tumor cells.

Kronman *et al.* (1970) obtained remarkable results in pure strain guinea pigs in which they had grafted hepatomas intramuscularly. Intradermal injections of living hepatoma cells (three injections per week on alternate weeks) induced an immunological reaction against the hepatomas.

2. Purified Antigens

Though several groups of chemists are now working on the extraction and characterization of "tumor-associated antigens," up until now they have only been testing their value in preventing the take of tumors. In our laboratory, Martyré and Halle-Pannenko (1968) have been working along these lines studying the antigens of the virus-induced Charlotte Friend leukemia.

3. Vaccination by Oncogenic Viruses

Even when the vaccination is commenced after the inoculation of the animal with the virus to induce a tumor, an antitumor effect can be achieved during the latent period. It has been shown that the admin-

istration of homologous virus during the course of the latent period to hamsters inoculated neonatally with SV40 or adenovirus reduced the incidence of tumors as compared to controls receiving only a single inoculation of virus (Eddy *et al.*, 1964; Deichman and Kluchareva, 1964; Allison, 1964). Repeated doses of adenovirus 7 in the latent period had an inhibitory effect on adenovirus 12 tumor induction (Periés *et al.*, 1966; Eddy, 1965).

4. Tumors Carrying Embryonic Antigens

As it is known that tumors of the digestive system, especially hepatomas, carry embryonic antigens (Abelev *et al.*, 1963), it would be very interesting to test embryonic extracts as antigens for active immunotherapy (Sedallian and Triaux, 1968).

B. NONSPECIFIC IMMUNOTHERAPY

A number of "adjuvants" have been used for nonspecific immunotherapy.

1. Freund's Adjuvant

Freund's adjuvant is the classical example of a stimulant of immunity (Freund, 1953). It has only rarely been used to try to cure tumors; that is, given after the establishment of the tumor. Hirano and his colleagues (1967) described how this adjuvant given 1 week after animals had been grafted with a lymphoma inhibited the tumor growth.

Allison (1964) observed that giving Freund's complete adjuvant to hamsters during the latent period following neonatal inoculation with adenovirus type 12 affected tumor production and the production of complement-fixing antibodies to adenovirus virions and T-antigens.

2. Zymosan

Zymosan, first used as an immunosuppressive agent (Mathé and Bernard, 1956), was later shown by Bradner *et al.* (1958) to be able to stimulate antitumor immunity and has been used to attempt to cure various nonspecific grafted tumors (Sokoloff *et al.*, 1961) as well as spontaneous tumors (Martin *et al.*, 1964). Under certain conditions, which are described later, it can have a beneficial effect.

3. BCG

BCG has been shown in our laboratory to prolong slightly the survival of mice carrying L 1210 leukemia, when it is injected 24 hours after a graft of 10^4 leukemic cells (Mathé, 1968; Mathé *et al.*, 1969b). Better